MentionFox
Home › Executive changes › Mereo BioPharma Group plc
Leadership changes · MREO · SEC Form 8-K, Item 5.02

Leadership changes at Mereo BioPharma Group plc (2026)

Before you join, sell to or invest in Mereo BioPharma Group plc

MentionFox check on Mereo BioPharma Group plc: only 1 source on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/mereo-biopharma-group

Check Mereo BioPharma Group plc before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Mereo BioPharma Group plc?

Who joined and who left Mereo BioPharma Group plc (MREO)? 1 filing reported on 2026-03-27, each cited to the company's own filing.

As of November 14, 2026, Mereo BioPharma Group plc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 27, 2026 (Form 8-K, March 27, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Mangrove Partners IM, LLC also filed stake reports on 2 other companies ↓

Sell to companies like Mereo BioPharma Group plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
Latest filing2026-03-27

Mereo BioPharma Group plc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-27. Every row below is cited to the filing it comes from, and this page adds each new change as Mereo BioPharma Group plc files it.

Also on the record for Mereo BioPharma Group plc

DateRecordFigureOur pageSource
October 28, 2026Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/3.4% of the class5%+ stakesSource
August 14, 2026Stake report, Schedule 13G/A, by EcoR1 Capital, LLC0.6% of the class5%+ stakesSource
May 15, 2026Stake report, Schedule 13G/A, by EcoR1 Capital, LLC8.4% of the class5%+ stakesSource
May 14, 2026Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/5.1% of the class5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC—5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Northpond Ventures, LP—5%+ stakesSource
February 13, 2026Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P.—5%+ stakesSource
January 9, 2026Stake report, Schedule 13G, by EcoR1 Capital, LLC9.4% of the class5%+ stakesSource
January 6, 2026Stake report, Schedule 13G, by 683 Capital Management, LLC8.18% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC10.2% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Mangrove Partners IM, LLC4.9% of the class5%+ stakesSource
August 14, 2025Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P.4.1% of the class5%+ stakesSource

Selling to them or working with them? See who runs Mereo BioPharma Group plc now and the warning signs.

Free to see. No signup.

Keep reading

More on Mereo BioPharma Group plc and the records around it.

Mereo BioPharma Group plc elsewhere on the record

Companies that share a holder

Want the whole picture on Mereo BioPharma Group plc?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Mereo BioPharma Group plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Mereo BioPharma Group plc covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 13 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-27Reportednot named in the filing8-K, 2026-03-27
Selling to Mereo BioPharma Group plc?

New leaders reset buying decisions — get the Full Report on Mereo BioPharma Group plc: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Mereo BioPharma Group plc

Hiring for a seat like this?

Find people with the same kind of experience as the senior executive at Mereo BioPharma Group plc, with the record behind each one.

Find candidates like senior executive at Mereo BioPharma Group plc

Every change, in the filing's words

Filed 2026-03-27 · 8-K

Reported

(the "Company") that she will not stand for re-election as a Director of the Board of Directors (the "Board") of the Company at the Company's 2026 annual general meeting of shareholders (the "2026 AGM"), scheduled for May 14, 2026.

Also stated in this filing

  • - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
  • On March 26, 2026, Dr. Annalisa Jenkins informed Mereo BioPharma plc.
  • Dr. Jenkins will continue to serve out the remainder of her term, which will expire immediately prior to the 2026 AGM.
  • Dr. Jenkins' decision not to stand for re-election did not result from any disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.

Tools for this story

Each opens in a new tab, filled in for Mereo BioPharma Group plc. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/mereo-biopharma-group
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
What changed at the top of Mereo BioPharma Group plc? (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/mereo-biopharma-group